Can Ariad Repeat?
On January 1, 2011 the Dow opened at 11,578 and on 12/31/2011 the Dow closed at 12,218. So the Dow rose just 5.5% for the year
On January 1, 2011 Ariad opened at $5.20 a share and Friday Ariad closed at $12.26 a share. That represents a whopping 135% increase for the year.
Why did Ariad beat the Dow so handidly?
In 2011, Ariad beat the Dow so handidly by accomplishing the following:
1- They announced that Ridaforolimus met it's endpoint in the Phase 111 trial
2- They announced very good results in Phase 1 in Ponatinib
3- They commenced a Phase 1/2 clinical trial in AP26113
4- They announced very good interim results in Ponatinib Phase 11
5- Bellicum announced good progress on their Prostrate Cancer Vacine, which utilizes Ariad's AP1903
5- Bellicum announced spectacular results for it's Graft Vs Host disease product candidate, which also utilizes AP1903
6- Merck filed an NDA with the FDA and the equivalent with the European Agency and both applications were acccepted
7- The FDA listed June 4th 2012 as the determination date for the Ridaforolimus NDA
8- Ariad successfully raised $254,000,000 through a secondary, and probably told Wall Street that it intends to keep complete ownership and control of both Ponatinib and AP26113.
This Dow vs Ariad financial result comparison reminds me of something "The Babe" once said in an interview. I believe it was in 1927, when "The Babe" hit 60 homeruns and was being paid the then incredible salary of $100,000 a year, a newcaster said to Ruth: Do you know that you are making more money that the President of The United States? Babe responded "I should, I am having a better year"
Now let's see if Ariad can repeat
